or Try an Advanced Search...

    Technical Analysis for CVM - Cel-Sci Corporation

    Grade Last Price % Change Price Change
    F 0.63 -2.67% -0.02
    CVM closed down 2.67 percent on Wednesday, November 20, 2024, on 1.4 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Down Down Down
    Historical CVM trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion -2.67%
    Up 3 Days in a Row Strength -2.67%
    Oversold Stochastic Weakness -2.67%
    Narrow Range Bar Range Contraction 11.27%
    Lower Bollinger Band Walk Weakness 11.27%
    Wide Bands Range Expansion 11.27%
    Oversold Stochastic Weakness 11.27%
    Calm After Storm Range Contraction 12.10%
    Older End-of-Day Signals for CVM ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 22 hours ago
    Rose Above 10 DMA about 22 hours ago
    Down 2 % about 22 hours ago
    Down 1% about 22 hours ago
    Up 5% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CVM Chart by TradingView
    Basic chart:

    Profile

    Cel-Sci Corporation Description

    CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company's principal product, Multikine, is under Phase III clinical trial for the treatment of head and neck cancer. The Multikine is an immunotherapeutic agent consisting of a mixture of cytokines that produce an anti-tumor immune response. It also develops Ligand Epitope Antigen Presentation System (LEAPs), a heteroconjugate technology that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, develops a peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Immunology Immune System Immunotherapy Vaccines Autoimmunity Rheumatoid Arthritis Vaccination Transplantation Cytokine Head And Neck Cancer Antigen Immune Response Allergies

    Is CVM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 7 CEL-SCI, FDA agree on Phase 3 trial design for cancer drug
    Nov 7 U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
    Oct 22 FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
    Oct 1 CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
    Sep 16 CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
    Sep 10 CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
    Aug 28 CVM: Start Your Engines – FDA Green Lights Confirmatory Registration Study
    Aug 15 Cel-Sci GAAP EPS of -$0.42 misses by $0.31
    Aug 15 CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
    Aug 15 Cel-Sci: Fiscal Q3 Earnings Snapshot
    See more CVM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.23
    52 Week Low 0.5402
    Average Volume 381,455
    200-Day Moving Average 1.38
    50-Day Moving Average 0.93
    20-Day Moving Average 0.76
    10-Day Moving Average 0.64
    Average True Range 0.05
    RSI (14) 30.56
    ADX 52.05
    +DI 12.66
    -DI 34.39
    Chandelier Exit (Long, 3 ATRs) 0.81
    Chandelier Exit (Short, 3 ATRs) 0.70
    Upper Bollinger Bands 1.01
    Lower Bollinger Band 0.50
    Percent B (%b) 0.25
    BandWidth 66.96
    MACD Line -0.10
    MACD Signal Line -0.09
    MACD Histogram -0.0073
    Fundamentals Value
    Market Cap 31.39 Million
    Num Shares 50 Million
    EPS -0.73
    Price-to-Earnings (P/E) Ratio -0.86
    Price-to-Sales 11797.42
    Price-to-Book 9.30
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.69
    Resistance 3 (R3) 0.69 0.67 0.68
    Resistance 2 (R2) 0.67 0.65 0.67 0.68
    Resistance 1 (R1) 0.65 0.64 0.64 0.65 0.67
    Pivot Point 0.63 0.63 0.62 0.63 0.63
    Support 1 (S1) 0.61 0.61 0.60 0.61 0.58
    Support 2 (S2) 0.59 0.60 0.59 0.58
    Support 3 (S3) 0.57 0.59 0.58
    Support 4 (S4) 0.57